Fármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafío!

Torres Dueñas, Diego; Espinosa Peña, Andrés Eduardo; Alarcón Forero, Laura Carolina; Niño Mantilla, María Eugenia; Cárdenas Angelone, María Eugenia

DSpace Principal
→
Colección de los Centros Asociados
→
Colombia
→
Instituto de Estudios Políticos - IEP - Cosecha
→
Ver ítem

dc.contributor	Torres Dueñas, Diego [0000066885]
dc.contributor	Espinosa Peña, Andrés Eduardo [0001356787]
dc.contributor	Niño Mantilla, María Eugenia [0000535885]
dc.contributor	Cárdenas Angelone, María Eugenia [0000066761]
dc.contributor	Niño Mantilla, María Eugenia [1R_FcOoAAAAJ]
dc.contributor	Torres Dueñas, Diego [0000-0002-8006-7461]
dc.contributor	Espinosa Peña, Andrés Eduardo [0000-0002-1584-7218]
dc.contributor	Alarcón Forero, Laura Carolina [0000-0002-0610-1174]
dc.contributor	Niño Mantilla, María Eugenia [0000-0003-2945-5175]
dc.contributor	Alarcón Forero, Laura Carolina [Laura-Alarcon-Forero]
dc.contributor	Niño Mantilla, María Eugenia [Maria-Nino-3]
dc.contributor	Grupo de Investigación en Ciencias y Educación en Salud
dc.creator	Torres Dueñas, Diego
dc.creator	Espinosa Peña, Andrés Eduardo
dc.creator	Alarcón Forero, Laura Carolina
dc.creator	Niño Mantilla, María Eugenia
dc.creator	Cárdenas Angelone, María Eugenia
dc.date	2020-10-27T14:20:38Z
dc.date	2020-10-27T14:20:38Z
dc.date	2010-04-11
dc.date.accessioned	2022-03-14T20:09:37Z
dc.date.available	2022-03-14T20:09:37Z
dc.identifier	2382-4603
dc.identifier	0123-7047
dc.identifier	http://hdl.handle.net/20.500.12749/10258
dc.identifier	instname:Universidad Autónoma de Bucaramanga UNAB
dc.identifier	repourl:https://repository.unab.edu.co
dc.identifier.uri	http://biblioteca-repositorio.clacso.edu.ar/handle/CLACSO/22300
dc.description	ResumenLa sepsis ocupa el primer lugar entre las causas de mortalidad en las unidades de cuidado intensivo, razón por el cual su comprensión ha sido objetivo de múltiples estudios. Esta patologÍa representa un reto para el médico ya que sus criterios diagnósticos nunca han podido llegar a un consenso, dificultando asÍ su enfoque terapéutico.[Torres-Dueñas D, Espinosa AE, Alarcón LC, Niño ME, Cárdenas ME. Fármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafÍo!.Palabras clave: Sepsis, SÍndrome de respuesta inflamatoria sistémica, Mediadores de inflamación, Terapéutica.
dc.format	application/pdf
dc.format	application/pdf
dc.language	spa
dc.publisher	Universidad Autónoma de Bucaramanga UNAB
dc.publisher	Facultad Ciencias de la Salud
dc.relation	https://revistas.unab.edu.co/index.php/medunab/article/view/440/422
dc.relation	https://revistas.unab.edu.co/index.php/medunab/article/view/440
dc.relation	Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10
dc.relation	Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17:389–93.
dc.relation	Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-55.
dc.relation	Poeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care 2004; 8:R409–13.
dc.relation	Vincent JL. Dear Sirs, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372–4.
dc.relation	Jaimes F, Garcés J, Cuervo J, Ramírez F, Ramírez J, Vargas A, et al. The systemic inflammatory response syndrome (SIRS) to identify infected patients in the emergency room. Intensive Care Med 2003; 29:1368–71.
dc.relation	Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. Crit Care Med 2008; 36:964-6.
dc.relation	Calandra T, Cohen J. The International Sepsis ForumConsensus Conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538–48.
dc.relation	Marshall JC. Sepsis research: Where have we gone wrong? Crit Care Resusc 2006; 8:241-3.
dc.relation	Jaimes F. A literature review of the epidemiology of sepsis in Latin America. Rev Panam Salud Publica 2005; 18:163 71.
dc.relation	Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980; 141:55-63.
dc.relation	Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225–30.
dc.relation	Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869–71.
dc.relation	Remick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 2003; 9:75–82.
dc.relation	Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tir4 gene. Science 1998; 282:2085–88.
dc.relation	Sansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 2006; 7:1237-42.
dc.relation	Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L622–L645.
dc.relation	Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993: 119:771–8.
dc.relation	Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032–37.
dc.relation	Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17–60.
dc.relation	Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B. Nitric Oxide Synthase Inhibition in Sepsis? Lessons Learned from Large-Animal Studies. Anesth Analg 2005; 101:488–98.
dc.relation	Torres-Dueñas D, Benjamim CF, Ferreira SH, Cunha FQ. Failure of neutrophil migration to infectious focus and cardiovascular changes on sepsis in rats: effects of the inhibition of nitric oxide production, removal of infectious focus, and antimicrobial treatment. Shock 2006; 25:267
dc.relation	(Suppl 1):107–19. 25. Alves-Filho JC, de Freitas A, Russo M, Cunha FQ. Toll-like receptor 4 signaling leads to neutrophil migration impairment in polymicrobial sepsis. Crit Care Med 2006; 34:461–70.
dc.relation	Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998: 351:929–33.
dc.relation	Lopez A. Lorente JA, Steingrub J. Bakker J. McLuckie A. Willatts S, et al. Multiple-center, randomized, placebo controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21–30.
dc.relation	Hoesel LM, Neff TA, Neff SB, Younger JG, Olle EW, Gao H, et al. A. harmful and protective roles of neutrophils in sepsis. Shock 2005; 24:40–7.
dc.relation	Fierro IM, Nascimento-DaSilva V, Arruda MA, Freitas MS, Plotkowski MC, Cunha FQ, et al. Induction of NOS in rat blood PMM in vivo and in vitro: modulation by tyrosine kinase and involvement in bactericidal activity. J Leukoc Biol 1999; 65:508-14.
dc.relation	Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
dc.relation	McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br JAnaesth. 2007; 98:163-75.
dc.relation	Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
dc.relation	Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003; 31(Suppl 1):S94-6.
dc.relation	Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009;37:19–25.
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.source	MedUNAB; Vol. 13 Núm. 1 (2010): Sepsis, Sedentarismo, Estado epiléptico; 13-16
dc.subject	Ciencias de la salud
dc.subject	Medicina
dc.subject	Ciencias médicas
dc.subject	Ciencias biomédicas
dc.subject	Ciencias de la vida
dc.subject	Innovaciones en salud
dc.subject	Investigaciones
dc.subject	Health Sciences
dc.subject	Medicine
dc.subject	Medical Sciences
dc.subject	Biomedical Sciences
dc.subject	Life Sciences
dc.subject	Innovations in health
dc.subject	Research
dc.subject	Medicina
dc.subject	Investigación
dc.subject	Ciencias biomédicas
dc.subject	Innovaciones en salud
dc.subject	Medidores de inflamación
dc.subject	Térapeutica
dc.subject	Síndrome de respuesta inflamatoria sistémica
dc.subject	Sepsis
dc.title	Fármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafío!
dc.type	info:eu-repo/semantics/article
dc.type	Artículo
dc.type	http://purl.org/coar/resource_type/c_7a1f
dc.type	Info:eu-repo/semantics/publishedVersion
dc.type	http://purl.org/redcol/resource_type/CJournalArticle